U.S Department of Defense Secures $21.5 Million BioThrax Anthrax Vaccine Order
Published: 10 Mar 2026
Author: Precedence Research
Emergent BioSolutions, a leading biodefense and specialty biopharmaceutical company operating in the U.S, announced that it has received an order worth $21.5 million from the U.S Department of Defense. This order entails the company’s obligation to make deliveries of its BioThrax anthrax vaccine for the 2026 fiscal year. This order comes as part of a continuous effort to bolster the country’s biodefense and strategic stockpile.
Strengthening National Biodefense
This order has been made under an existing contract referred to as an indefinite-delivery/indefinite-quantity contract. This contract allows the Department of Defense to procure vaccine doses as they require them to meet the demand and requirements of military personnel and other at-risk groups. The BioThrax vaccine has been extensively researched and used as a preventive measure against anthrax infection. “This order is a testament to the U.S government’s continued trust in BioThrax as a key component in national security”, said Fuad El-Hibri, CEO of Emergent BioSolutions.
According to Precedence Research, the global anthrax vaccine market size was calculated at USD 14.18 billion in 2025 and is predicted to reach around USD 22.34 billion by 2035, expanding at a CAGR of 4.65% from 2026 to 2035 as the demand grows for strategic stockpile maintenance and protection of military and high risk populations.
Operational and Strategic Impact
This order is significant because it will allow for timely production and distribution of doses of the vaccine, providing military personnel and other approved individuals with the necessary prophylactic measures to counter anthrax. The administration of the BioThrax vaccine is part of a larger national program that includes emergency response planning, stockpiling and vaccination programs for first responders and laboratory workers. Analysts have noted that the anthrax vaccine segment has continued to receive stable market demand owing to the continued need for preventative and strategic public health initiatives, even in the absence of outbreaks.
This order marks a significant milestone for Emergent BioSolutions, cementing its position as a key ally to the U.S government in ensuring BioThrax remains accessible to military and proactive initiatives. This announcement underscores the continued relevance of anthrax vaccination in the U.S defense strategies and the company’s continued commitment to public health.
A recent report by Precedence Research highlights that the anthrax vaccine market is benefiting from sustained government procurement and ongoing biodefense preparedness efforts.